Member Info for Bella6532

Good...because any new and significant information must be given to the markets first...
Does this mean then that the information they are not going to impart will be significant...yes..of course it will be..it's a trial.

'Recommended latest time and date for requesting withdrawal of Open Offer Entitlements and Excess CREST Open Offer Entitlements from CREST
4.30 p.m. on 1 November 2022

Latest time and date for depositing Open Offer Entitlements into CREST
3.00 p.m. on 2 November 2022

Latest time and date for splitting Application Forms (to satisfy bona fide market claims only)
3.00 p.m. on 3 November 2022

Latest time and date for receipt of completed Application Forms and payment in full from Qualifying Shareholders under the Open Offer or settlement of relevant CREST instruction (as appropriate)
11.00 a.m. on 7 November 2022

Announcement of the results of the Open Offer
8 November 2022

Admission effective and dealings in the Open Offer Shares expected to commence on AIM
9 November 2022

Expected date for crediting of the Open Offer Shares in uncertificated form to CREST stock accounts
9 November 2022

Expected date of dispatch of share certificates in respect of the Open Offer Shares
by 16 November 2022'

Above may be subject to change..

Now at what point would you RNS trial results...or any other interesting news.

Fundraise investor HCI is a division of Susquehanna

Should see some nice big late trades...

Common Avacta...let's break 112 today...

We now know...
All good and SP should recover quickly once finalised.

Sorry - here's the link

https://gtr.ukri.org/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2

In fact I think you will find Avacta listed in all of these: (The amounts relate to fund)
£5,089,889 Mar 14 - Mar 20
Maximising Therapeutic Utility for Rheumatoid Arthritis using genetic and genomic tissue responses to stratify medicines.
MRC award to Queen Mary, University of London and Costantino Pitzalis

£2,761,091 Jan 11 - Dec 14
Innovation and Knowledge Centre Regenerative Therapies and Devices Tranche 1 IKC RTD
EPSRC award to University of Leeds and John Fisher

£158,620 May 12 - Oct 14
PROMPT SEPSIS : Partnership for Rapid On-site Microfluidic POC Test for Sepsis
EPSRC award to University of Liverpool and Enitan Carrol

£5,840,286 Sep 11 - Dec 16
EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies
EPSRC award to University College London and Nigel Titchener-Hooker

£4,893,965 Oct 09 - Oct 14
Regenerative Therapies and Devices
EPSRC award to University of Leeds and John Fisher

£500,000 Mar 15 - Aug 16
Tropical Infectious Disease Consortium: Sustaining, Expanding and Accelerating Product Development
MRC award to Liverpool School of Tropical Medicine and Stephen Ward

£6,415,000 Apr 13 - Mar 18
Understanding signalling pathways mutated in inherited disorders
MRC award to University of Dundee and Dario Renato Alessi

£2,930,175 Mar 91 - Mar 13
Role of PDK1 in the PtdIns 3-kinase-dependent protein kinase cascade that mediates actions of insulin & survival factors
MRC award to MRC Protein Phosphorylation Unit and Dario Renato Alessi

£6,201,742 Apr 02 - Mar 12
Understanding the functions of LKB1 and other protein kinases mutated in inherited diseases
MRC award to MRC Protein Phosphorylation Unit and Dario Renato Alessi

£386,000 Feb 09 - Dec 11
Exploitation of mouse models to validate protein kinases as drug targets
MRC award to MRC Protein Phosphorylation Unit and Dario Renato Alessi

£2,808,683 Aug 15 - Dec 19
MICA: The Newcastle Proximity Laboratory
MRC award to Newcastle University and Andrew Graham Hall

£500,000 Mar 14 - Aug 15
Liverpool School of Tropical Medicine Confidence in Concept 2013
MRC award to Liverpool School of Tropical Medicine and Stephen Ward

£1,813,535 Apr 12 - Mar 16
Innovation and Knowledge Centre Regenerative Therapies and Devices Tranche 2 IKC RTD
EPSRC award to University of Leeds and John Fisher

£8,427,000 May 08 - Mar 21
Specificity in the ubiquitin system
MRC award to MRC Laboratory of Molecular Biology and David Komander

Mr. A....the reason I posted under a separate heading was because the link to the abstract related to a joint collaboration between Avacta and Novopath with Newcastle University who were setting up a "Proximity Laboratory" in a busy NHS service department (see below)...and you are correct it was from 2021

MICA: The Newcastle Proximity Laboratory
Lead Research Organisation: Newcastle University
Department Name: Translational and Clinical Res Institute
Abstract
The introduction of new scientific methods has shown that many diseases are much more heterogeneous than originally believed and that differences between cases can have a marked influence on the way that patients respond favourably to treatment. This has led to the concept of "stratified" medicine in which treatment is adjusted to meet the needs of individual patients. This approach ensures that treatment is only given to patients who are likely to respond and has both clinical and economic benefits, as unnecessary toxicity will be avoided and expensive new therapies are conserved.

The introduction of stratified medicine requires the development of diagnostic techniques which can be used in clinical practice. In order for a new test to be adopted it has to be validated using "real-life" samples and adapted so that it can be used reliably in routine clinical laboratories. For many tests this requires input from experts in Cellular Pathology. However, in recent years, due largely to service pressures, many clinical and non-clinical specialists in this discipline have been unable to dedicate time to maintaining their knowledge in Molecular Pathology or to undertake research themselves.

Our bid responds to the three areas for need identified by the MRC in order to ensure that the development of new diagnostic tests keeps pace with the demands of stratified medicine; restoration of the proximity between clinical and research activity; development of a clear path between discovery science and clinical application and addressing the training needs of laboratory staff.

PROXIMITY
We will establish a "Proximity Laboratory" in a busy NHS service department, which is adjacent to the University Medical Faculty, involving both University and clinical staff. Three satellite laboratories will be established in the Medical School and the Transplant Institute (Freeman Hospital), to provide a well-equipped training and research environment close to the discovery laboratories.

Vanilla...open the link I just posted then click on Outcome then click on Collaboration. Scroll down and you will find the details I also just posted.

NovoPath Proximity Lab - AVACTA (2021 - Still Active)
Organisation Avacta Group
Country United Kingdom
Sector Private
PI Contribution NovoPath to provide Fibroblast activation protein (FAP), Immunohistochemistry (IHC), DAB staining on a per sample basis for internal and external Avacta clinical trial samples. Processing, embedding and microtomy of Newcastle trial samples or staining of external sample blocks or slides. All staining will be reviewed and reported by a consultant Pathologist.
Collaborator Contribution /
Impact /
Start Year 2021

https://gtr.ukri.org/project/F3E76488-117E-439C-A0AD-7A924BE5AD8F#/tabOverview

If you open the abive and click on companies Avacta are one of the collaborators along with some other interesting names..

'first step in Avacta’s M&A-led growth strategy for its Diagnostics Division.'

Any thoughts on what their next M&A might be...
Part of Deepverge could be going cheap right now..haha..

Chesh...gotcha comments re Fin fuming and potentially retiring in 6 months. My comments were about where we are now and the obvious creation of two separate parts of tge company. This makes accountability of individuals performance easier and should changes be needed it doesn't affect the whole company going forward.
It also creates some internal competition too...perform we support...under-perform and we slice...

Mates rates...worked throughout today...

Shorters closing...

It's just an old Avacta logo filed in Sept 2014. Doesn't seem to have any relevance now. The EU trademark site has details. Just search using this number EU013285259 but leave off the EU.

Mr A...'What's the upside down white V on red background used for?'...I think it's supposed to be an A without the cross bar. An EUTM (EU Trade mark when UK was in tge EU). What it was for us anyones guess...

Instead of having one person in charge of two completely different sides of the business, we now have each side of the business with it's own head which, as I said early, leads to far more accountability.

The historic transactions is peanuts and many companies make reporting mistakes especially if only one person in the organisation knows the rules which is nearly always the case. I suspect as said due diligence has been done to either cover buts for a T/O or RTO linked to fundraise/investment. I just get the the feeling there is more than just a simple fundraiser going on.